Identification of P2Y12 single-nucleotide polymorphisms and their influences on the variation in ADP-induced platelet aggregation

Thrombosis Research

Volumn 127, Issue 3, 2011, Pages 220-227

  Lee, Su Jun ^a   Jung, Il Sun ^a   Jung, Eun Ji ^a   Choi, Ji Yeop ^a   Yeo, Chang Woo ^a   Cho, Doo Yeoun ^a,c   Kim, Yang Weon ^a   Lee, Sang Seop ^a   Shin, Jae Gook ^a,b  

^a Inje University College of Medicine   (South Korea)

^b Inje University College of Medicine   (South Korea)

^c Ajou University School of Medicine   (South Korea)

Author keywords

Aggregation; Haplotype; Linkage Disequilibrium; P2Y12; Platelet; SNPs; Tag SNPs

Indexed keywords

ADENOSINE DIPHOSPHATE; DNA; MESSENGER RNA; PURINERGIC P2Y12 RECEPTOR;

5' UNTRANSLATED REGION; ADULT; ARTICLE; DNA SEQUENCE; EXON; GENETIC ANALYSIS; GENETIC VARIABILITY; HAPLOTYPE; HUMAN; INTRON; KOREA; MALE; NORMAL HUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; THROMBOCYTE AGGREGATION;

ADENOSINE DIPHOSPHATE; ADULT; HAPLOTYPES; HUMANS; KOREA; LINKAGE DISEQUILIBRIUM; MALE; PLATELET AGGREGATION; POLYMORPHISM, SINGLE NUCLEOTIDE; RECEPTORS, PURINERGIC P2Y12; YOUNG ADULT;

EID: 79951956275     PISSN: 00493848     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.thromres.2010.11.023     Document Type: Article

References (35)

1. Barrett NE, Holbrook L, Jones S, Kaiser WJ, Moraes LA, Rana R, et al. Future innovations in anti-platelet therapies. Br J Pharmacol 2008;154:918-39. (Pubitemid 351915054)
2. Nurden AT, Nurden P. Inherited disorders of platelets: an update. Curr Opin Hematol 2006;13:157-62.
3. Bhatt DL, Topol EJ. Scientific and therapeutic advances in antiplatelet therapy. Nat Rev Drug Discov 2003;2:15-28. (Pubitemid 37361621)
4. Jin J, Daniel JL, Kunapuli SP. Molecular basis for ADP-induced platelet activation. II. The P2Y1 receptor mediates ADP-induced intracellular calcium mobilization and shape change in platelets. J Biol Chem 1998;273:2030-4. (Pubitemid 28069249)
5. Daniel JL, Dangelmaier C, Jin J, Ashby B, Smith JB, Kunapuli SP. Molecular basis for ADP-induced platelet activation. I. Evidence for three distinct ADP receptors on human platelets. J Biol Chem 1998;273:2024-9.
6. Nurden P, Savi P, Heilmann E, Bihour C, Herbert JM, Maffrand JP, et al. An inherited bleeding disorder linked to a defective interaction between ADP and its receptor on platelets: its influence on glycoprotein IIb-IIIa complex function. J Clin Invest 1995;95:1612-22.
7. Cattaneo M, Lombardi R, Zighetti ML, Gachet C, Ohlmann P, Cazenave JP, et al. Deficiency of (33P)2MeS-ADP binding sites on platelets with secretion defect, normal granule stores and normal thromboxane A2 production. Evidence that ADP potentiates platelet secretion independently of the formation of large platelet aggregates and thromboxane A2 production. Thromb Haemost 1997;77:986-90.
8. Cattaneo M, Gachet C. ADP receptors and clinical bleeding disorders. Arterioscler Thromb Vasc Biol 1999;19:2281-5. (Pubitemid 29477827)
9. Hollopeter G, Jantzen HM, Vincent D, Li G, England L, Ramakrishnan V, et al. Identification of the platelet ADP receptor targeted by antithrombotic drugs. Nature 2001;409:202-7. (Pubitemid 32144286)
10. Heptinstall S, Mulley GP. Adenosine diphosphate induced platelet aggregation and release reaction in heparinized platelet rich plasma and the influence of added citrate. Br J Haematol 1977;36:565-5671.
11. O'Donnell CJ, Larson MG, Feng D, Sutherland PA, Lindpaintner K, Myers RH, et al. Framingham Heart Study. Genetic and environmental contributions to platelet aggregation: the Framingham heart study. Circulation 2001;103:3051-6.
12. Hetherington SL, Singh RK, Lodwick D, Thompson JR, Goodall AH, Samani NJ. Dimorphism in the P2Y1 ADP receptor gene is associated with increased platelet activation response to ADP. Arterioscler Thromb Vasc Biol 2005;25:252-7. (Pubitemid 40054285)
13. Rudez G, Bouman HJ, van Werkum JW, Leebeek FW, Kruit A, Ruven HJ, et al. Common variation in the platelet receptor P2RY12 gene is associated with residual on-clopidogrel platelet reactivity in patients undergoing elective percutaneous coronary interventions. Circ Cardiovasc Genet 2009;2:515-21.
14. Sibbing D, Koch W, Gebhard D, Schuster T, Braun S, Stegherr J, et al. Cytochrome 2C19*17 allelic variant, platelet aggregation, bleeding events, and stent thrombosis in clopidogrel-treated patients with coronary stent placement. Circulation 2010;121:512-8.
15. Rudez G, Pons D, Leebeek F, Monraats P, Schrevel M, Zwinderman A, et al. Platelet receptor P2RY12 haplotypes predict restenosis after percutaneous coronary interventions. Hum Mutat 2008;29:375-80. (Pubitemid 351364939)
16. Angiolillo DJ, Fernandez-Ortiz A, Bernardo E, Ramírez C, Cavallari U, Trabetti E, et al. Lack of association between the P2Y12 receptor gene polymorphism and platelet response to clopidogrel in patients with coronary artery disease. Thromb Res 2005;116:491-7. (Pubitemid 41330814)
17. von Beckerath N, von Beckerath O, Koch W, Eichinger M, Schömig A, Kastrati A. P2Y12 gene H2 haplotype is not associated with increased adenosine diphosphate-induced platelet aggregation after initiation of clopidogrel therapy with a high loading dose. Blood Coagul Fibrinolysis 2005;16:199-204. (Pubitemid 40547275)
18. Cuisset T, Frere C, Quilici J, Morange PE, Saut N, Lambert M, et al. Role of the T744C polymorphism of the P2Y12 gene on platelet response to a 600-mg loading dose of clopidogrel in 597 patients with non-ST-segment elevation acute coronary syndrome. Thromb Res 2007;120:893-9. (Pubitemid 47432706)
19. Staritz P, Kurz K, Stoll M, Giannitsis E, Katus HA, Ivandic BT. Platelet reactivity and clopidogrel resistance are associated with the H2 haplotype of the P2Y12-ADP receptor gene. Int J Cardiol 2009;133:341-5.
20. Bura A, Bachelot-Loza C, Ali FD, Aiach M, Gaussem P. Role of the P2Y12 gene polymorphism in platelet responsiveness to clopidogrel in healthy subjects. J Thromb Haemost 2006;4:2096-7. (Pubitemid 44226807)
21. Fontana P, Dupont A, Gandrille S, Bachelot-Loza C, Reny JL, Aiach M, et al. Adenosine diphosphate-induced platelet aggregation is associated with P2Y12 gene sequence variations in healthy subjects. Circulation 2003;108:989-95.
22. Lee SJ, Kim WY, Choi JY, Lee SS, Shin JG. Identification of CYP19A1 single-nucleotide polymorphisms and their haplotype distributions in a Korean population. J Hum Genet 2010;55:189-93.
23. Gabriel SB, Schaffner SF, Nguyen H, Moore JM, Roy J, Blumenstiel B, et al. The structure of haplotype blocks in the human genome. Science 2002;296:2225-9. (Pubitemid 34680308)
24. Fontana P, Gaussem P, Aiach M, Fiessinger JN, Emmerich J, Reny JL. P2Y12 H2 haplotype is associated with peripheral arterial disease: a case-control study. Circulation 2003;108:2971-3.
25. Ziegler S, Schillinger M, Funk M, Felber K, Exner M, Mlekusch W, et al. Association of a functional polymorphism in the clopidogrel target receptor gene, P2Y12, and the risk for ischemic cerebrovascular events in patients with peripheral artery disease. Stroke 2005;36:1394-9.
26. Schettert IT, Pereira AC, Lopes NH, Hueb WA, Krieger JE. Association between platelet P2Y12 haplotype and risk of cardiovascular events in chronic coronary disease. Thromb Res 2006;118:679-83. (Pubitemid 44647093)
27. Jin J, Kunapuli SP. Coactivation of two different G protein-coupled receptors is essential for ADP-induced platelet aggregation. Proc Natl Acad Sci USA 1998;95:8070-4. (Pubitemid 28326067)
28. Savage B, Almus-Jacobs F, Ruggeri ZM. Specific synergy of multiple substrate-receptor interactions in platelet thrombus formation under flow. Cell 1998;94:657-66. (Pubitemid 28427584)
29. Jackson SP. The growing complexity of platelet aggregation. Blood 2007;109:5087-95. (Pubitemid 46890522)
30. Malek LA, Kisiel B, Spiewak M, Grabowski M, Filipiak KJ, Kostrzewa G, et al. Coexisting polymorphisms of P2Y12 and CYP2C19 genes as a risk factor for persistent platelet activation with clopidogrel. Circ J 2008;72:1165-9. (Pubitemid 351957086)
31. Gogos JA, Hsu T, Bolton J, Kafatos FC. Sequence discrimination by alternatively spliced isoforms of a DNA binding zinc finger domain. Science 1992;257:1951-5.
32. ΔΔCT method. Methods 2001;25:402-8.
33. Collet JP, Hulot JS, Pena A, Villard E, Esteve JB, Silvain J, et al. Cytochrome P450 2C19 polymorphism in young patients treated with clopidogrel after myocardial infarction: a cohort study. Lancet 2009;373:309-17.
34. Bouman HJ, van Werkum JW, Rudez G, Leebeek FW, Kruit A, Hackeng CM, et al. The influence of variation in the P2Y12 receptor gene on in vitro platelet inhibition with the direct P2Y12 antagonist cangrelor. Thromb Haemost 2010;103:379-86.
35. Michelson AD, Linden MD, Furman MI, Li Y, Barnard MR, Fox KL, et al. Evidence that pre-existent variability in platelet response to ADP accounts for 'clopidogrel resistance'. J Thromb Haemost 2006;5:75-81.